Complete remission of a high risk metastatic rhabdomyosarcoma in an adolescent treated with a liposomal (Myocet®) regimen

From: Archive of Clinical Cases 2014; 1(2):52-55 () Abstract We report the case of a very high risk metastatic rhabdomyosarcoma teenager treated with induction therapy using only liposomal doxorubicin (Myocet®) because of his extremely bad condition. A near complete remission was obtained after 2 courses. Then he received conventional chemotherapy according to the EpSSG protocol,…
Continue Reading »

Declining Childhood and Adolescent Cancer Mortality

Declining Childhood and Adolescent Cancer Mortality Malcolm A. Smith, MD, PhD; Sean F. Altekruse, DVM, PhD; Peter C. Adamson, MD; Gregory H. Reaman, MD; and Nita L. Seibel, MD To go to the web link at Wiley Online Library, Click Here Treatment of childhood cancer is 1 of the important success stories of 20th century…
Continue Reading »

YAPping About Differentiation Therapy in Muscle Cancer

YAPping About Differentiation Therapy in Muscle Cancer MN Svalina, C Keller - Cancer Cell, 2014 This article is linked to "The Hippo Transducer YAP1 Transforms Activated Satellite Cells and Is a Potent Effector of Embryonal Rhabdomyosarcoma Formation" (Tremblay, ) which was the basis for Samantha Olson's article "Cause of Rare Childhood Cancer, Rhabdomyosarcoma, Discovered: May…
Continue Reading »

Treating Cancer With Bacteria Shows Real Promise

In a groundbreaking study, researchers say injecting bacteria into a tumor helped shrink it Alice Park - August 13, 2014 Time Online Bacteria are generally considered more foe than friend, but that may change, if results from a pioneering study are confirmed. Reporting in the journal Science Translational Medicine, scientists led by Dr. Saurabh Saha,…
Continue Reading »

Gene Mutation Linked to Aggressive Form of Sarcoma Affecting Children and Young Adults

From OnCancer - Memorial Sloan Kettering Cancer Center By Eva Kiesler, PhD, Science Writer/Editor | Wednesday, August 6, 2014 Researchers at Memorial Sloan Kettering have discovered a gene mutation that may explain why a subset of patients with rhabdomyosarcoma — a rare cancer that affects mainly children and young adults — have a particularly aggressive…
Continue Reading »

Cause Of Rare Childhood Cancer, Rhabdomyosarcoma, Discovered; May Lead To Treatment In Near Future

By Samantha Olson | Jul 31, 2014 12:00 AM EDT - Medical Daily Read on the Web here  Scientists Discover Cause Of Rare Childhood Cancer The cause of a rare childhood muscle cancer has finally been discovered after three years. The cancer-causing trigger has been found after three years of searching for a better…
Continue Reading »

New Article From Dr. Keller’s Lab

A very interesting article has just been published by Dr. Keller's laboratory. The article is titled "Lineage of origin in rhabdomyosarcoma informs pharmacological response." Abstract Lineage or cell of origin of cancers is often unknown and thus is not a consideration in therapeutic approaches. Alveolar rhabdomyosarcoma (aRMS) is an aggressive childhood cancer for which the…
Continue Reading »

Rhabdomyosarcoma in adolescent and young adult patients: current perspectives

An important and interesting article on Rhabdomyosarcoma in adolescents and young adults by Daniela Egas-Bejar and Winston W. Huh from The Children's Cancer Hospital, UT MD Anderson Cancer Center in Houston. This article was published in Adolescent Health, Medicine and Therapeutics, 17 July 2014. You can download the PDF here < adol-adult-RMS >. Abstract: Rhabdomyosarcoma (RMS), a…
Continue Reading »

Temsirolimus combination improved event-free survival in rhabdomyosarcoma

June 1, 2014 (ASCO-2014) CHICAGO — The addition of temsirolimus to vinorelbine and cyclophosphamide led to increased event-free survival at 6 months and 1 year compared with vinorelbine and cyclophosphamide plus bevacizumab in patients with first relapse rhabdomyosarcoma. “Children and adolescents who are diagnosed with rhabdomyosarcoma do very poorly following relapse, with a median survival…
Continue Reading »

Researchers Discover New Therapy for a Common Childhood Cancer that has Fewer Side Effects

This weekend at the American Society of Clinical Oncology (ASCO) Annual Meeting, Children’s Oncology Group (COG) researchers will present promising findings from an international study that has identified a new therapy for treating rhabdomyosarcoma, a common childhood cancer. The therapy has fewer harsh side effects, meaning it lessens the chance of infections, need for blood…
Continue Reading »
Skip to toolbar